BRISTOL-MYERS SQUIBB COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.7 USD | -8.52% |
|
-7.56% | -12.98% |
| 07:58pm | Sector Update: Health Care Stocks Drop in Afternoon Trading | MT |
| 07:56pm | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | 45.78B | Sales 2025 * | 46.27B | Capitalization | 99.03B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.66B | Net income 2025 * | 10.37B | EV / Sales 2024 * | 3.04 x |
| Net Debt 2024 * | 39.92B | Net Debt 2025 * | 31.58B | EV / Sales 2025 * | 2.82 x |
| P/E ratio 2024 * |
-25.5
x | P/E ratio 2025 * |
8.82
x | Employees | 34,100 |
| Yield 2024 * |
4.95% | Yield 2025 * |
5.17% | Free-Float | 69.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | -8.52% | ||
| 1 week | -7.56% | ||
| Current month | -17.67% | ||
| 1 month | -14.55% | ||
| 3 months | -10.00% | ||
| 6 months | -21.13% | ||
| Current year | -12.98% |
1 week
44.37
49.56
1 month
44.3754.48
Current year
44.3755.04
1 year
44.3769.74
3 years
44.3781.44
5 years
42.4881.44
10 years
42.4881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 215 M€ | +12.15% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 18 M€ | +3.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 44.65 | -8.62% | 28 865 021 |
| 24-04-24 | 48.86 | -0.27% | 16,057,141 |
| 24-04-23 | 48.99 | -0.31% | 9,153,290 |
| 24-04-22 | 49.14 | +0.43% | 7,929,534 |
| 24-04-19 | 48.93 | +1.30% | 10,303,913 |
Delayed Quote Nyse, April 25, 2024 at 01:47 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
06:59am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
48.86
USD
Average target price
56.2
USD
Spread / Average Target
+15.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.98% | 99.03B | |
| +24.17% | 562B | |
| -6.15% | 358B | |
| +20.37% | 322B | |
| +8.07% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -11.41% | 149B | |
| -6.25% | 146B |
- Stock Market
- Equities
- BMY Stock
